Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 12, 2004, Pages 4574-4581

  Kang, Cheol In ^a   Kim, Sung Han ^a   Wan, Beom Park ^a   Lee, Ki Deok ^a   Kim, Hong Bin ^a   Kim, Eui Chong ^a,b   Oh, Myoung Don ^a,b   Choe, Kang Won ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM; CEFOXITIN; CEPHALOSPORIN; CIPROFLOXACIN; IMIPENEM;

ADOLESCENT; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BLOOD CULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; MORTALITY; NEUTROPENIA; PERITONITIS; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SEPSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; APACHE; BACTEREMIA; BETA-LACTAMASES; CROSS INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 9644310222     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.12.4574-4581.2004     Document Type: Article

References (32)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20:864-874.
2. Burwen, D. R., S. N. Banerjee, and R. P. Gaynes. 1994. The National Nosocomial Infections Surveillance System. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J. Infect. Dis. 170:1622-1625.
3. Bush, K. 2001. New β-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin. Infect. Dis. 32:1085-1089.
4. Corbella, X., A. Montera, M. Pujol, M. A. Dominguez, J. Ayats, M. J. Argerich, F. Garrigosa, J. Ariza, and F. Gudiol. 2000. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J. Clin. Microbiol. 38:4086-4095.
5. Eisenstein, B. I., and D. F. Zaleznik. 2000. Enterobacteriaceae, p. 2294-2310. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 5th ed. Churchill Livingstone, Philadelphia, Pa.
6. Garner, J. S., W. R. Jarvis, T. G. Emori, T. C. Horan, and J. M. Hughes. 1988. CDC definitions for nosocomial infections. Am. J. Infect. Control 16:128-140.
7. Itokazu, G. S., J. P. Quinn, C. Bell-Dixon, F. M. Kahan, and R. A. Weinstein. 1996. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin. Infect. Dis. 23:779-784.
8. Jacoby, G. A., and A. A. Medeiros. 1991. More extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 35:1697-1704.
9. Jorgensen, J. H., J. D. Turnidge, and J. A. Washington. 1999. Antibacterial susceptibility tests: dilution and disk diffusion methods, p. 1526-1543. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology. 7th ed. American Society for Microbiology, Washington, D.C.
10. Karas, J. A., D. G. Pillay, D. Muckart, and A. W. Sturm. 1996. Treatment failure due to extended-spectrum beta-lactamase. J. Antimicrob. Chemother. 37:203-204.
11. Kim, B. N., J. H. Woo, M. N. Kim, J. Ryu, and Y. S. Kim. 2002. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteremia. J. Hosp. Infect. 52:99-106.
12. Kim, Y. K., H. Pai, H. J. Lee, S. E. Park, E. H. Choi, J. Kim, J. H. Kim, and E. C. Kim. 2002. Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob. Agents Chemother. 46:1481-1491.
13. Knaus, W. A., E. A. Drapier, D. P. Wagner, and J. E. Zimmerman. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-829.
14. Knothe, H., P. Shah, V. Kremery, M. Antal, and S. Mitsuhashi. 1983. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11:315-317.
15. Lautenbach, E., J. B. Patel, W. B. Bilker, P. H. Edelstein, and N. O. Fishman. 2001. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. 32:1162-1171.
16. Meyer, K. S., C. Urban, J. A. Eagen, B. J. Berger, and J. J. Rahal. 1993. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann. Intern. Med. 119:353-358.
17. National Committee for Clinical Laboratory Standards. 2000. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A7, 7th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard. NCCLS document M100-S13. National Committee for Clinical Laboratory Standards. Wayne, Pa.
19. Naumovski, L., J. P. Quinn, D. Miyashiro, M. Patel, K. Bush, S. B. Singer, D. Graves, T. Palzkill, and A. M. Arvin. 1992. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob. Agents Chemother. 36:1991-1996.
20. Paterson, D. L. 2000. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin. Microbiol. Infect. 6:460-463.
21. Paterson, D. L., W-C. Ko, A. V. Gottberg, S. Mohapatra, J. M. Casellas, H. Goossens, L. Mulazimoglu, G. Trenholme, K. P. Klugman, R. A. Bonomo, L. B. Rice, M. M. Wagener, J. G. McCormack, and V. L. Yu. 2004. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann. Intern. Med. 140:26-32.
22. Paterson, D. L., W.-C. Ko, A. V. Gottberg, J. M. Casellas, L. Mulazimoglu, K. P. Klugman, R. A. Bonomo, L. B. Rice, J. G. McCormaek, and V. L. Yu. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39:2206-2212.
23. Pena, C., M. Pujol, C. Ardanuy, A. Ricart, R. Pallares, J. Linares, J. Ariza, and F. Gudiol. 2001, An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase. J. Hosp. Infect. 47:53-59.
24. Pena, C., M. Pujol, C. Ardanuy, A. Ricart, R. Pallares, J. Linares, J. Ariza, and F. Gudiol. 1998. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 42:53-58.
25. Rice, L. B., L. L. Carias, R. A. Bonomo, D. M. Shlaes. 1996. Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy. J. Infect. Dis. 173:151-158.
26. Schiappa, D. A., M. K. Hayden, M., G. Matushek, F. N. Hashemi, J. Sullivan, K. Y. Smith, D. Miyashiro, J. P. Quinn, R. A. Weinstein, and G. M. Trenholme. 1996. Ceftazidime-resistant Klebsiella pneumoniae and Eschenchia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J. Infect. Dis. 174:529-536.
27. Steward, C. D., J. K. Rasheed, S. K. Hubert, J. W. Biddle, P. M. Raney, G. J. Andersen, P. P. Williams, K. L. Brittain, A. Oliver, J. E. McGowan, and F. C. Tenover. 2001. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum β-lactamase detection methods. J. Clin. Microbiol. 39:2864-2872.
28. Thauvin-Eliopoulos, C., M. F. Tripodi, R. C. Moellering, and G. M. Eliopoulos. 1997. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 41:1053-1057.
29. Thomason, K. S., and C. C. Sanders. 1992. Detection of extended-spectrum β-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests. Antimicroh. Agents Chemother. 36:1877-1882.
30. Troillet, N., M. H. Samore, and Y. Carmeli. 1997. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin. Infect. Dis. 25:1094-1098.
31. Tzelepi, E., P. Giakkoupi, D. Sofianou, V. Loukova, A. Kemeroglou, and A. Tsakris. 2000. Detection of extended-spectrum β-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J. Clin. Microbiol. 38:542-546.
32. Wong-Beringer, A., J. Hindler, M. Loeloff, A. M. Queenan, N. Lee, D. A. Pegues, J. P. Quinn, and K. Bush. 2002. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin. Infect. Dis. 34:135-146.